giovedì, 3 dicembre 2020
Medinews
1 Marzo 2018

Flexible Scope Indication Approved for Bladder Imaging Agent

February 26, 2018 – The FDA recently approved a supplemental new drug application (sNDA) for Blue Light Cystoscopy (BLC) with Cysview for surveillance of bladder cancer, according to Photocure, the manufacturer of Cysview. Photocure sought to expand the label to include use in the outpatient setting to detect the recurrence of bladder cancer using a flexible cystoscope and received a priority review for the sNDA in October 2017. The agent was previously … (leggi tutto)

TORNA INDIETRO